Known targets — ChEMBL curated mechanism
ABCC8ACEADORA1ADORA2AADORA2BADORA3ALDH5A1ALOX5ALOX5APATP4AATP4BBRAFCA1CA12CA2CA4CYSLTR1DHFRDPEP1EDNRAEDNRBESR2F10FDPSFGF1GABBR1GABBR2GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGARTGNRHRGSC1HMGCRIMPDH1IMPDH2KCNJ11LY96NOD2NR3C1NS3NS4ANS5bP2RY1P2RY12P2RY2P2RY4P2RY6PBP2XPDE3APDE3BPDE4APDE4BPDE4CPDE4DPDK1PDK2PDK3PDK4PPARGPPATPTGIRPTGS1PTGS2RAF1RYR1RYR3SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASERPINC1SLC12A1SLC12A3SYKTHRATHRBTLR3TLR4TLR9TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYMSVKORC1XDHblablaIMP-1blaOXA-33blaOXA-58blaT-3blaT-4blaT-5blaT-6dacAdacBdacCfolAfolPfolP1ftsIfusAgaggyrAgyrBmecAmrcAmrcBmrdApbp1apbp1bpbp2pbp2apbp2bpbp3pbp4pbpApbpBpbpCpbpFpolponBrplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpoArpoBrpoCrpoZrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Azelaic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG known ✓ | P37231 | 6/20 | 0.52 |
| ▸ | PDE4A known ✓ | P27815 | 1/20 | 0.52 |
| ▸ | PDE3A known ✓ | Q14432 | 1/20 | 0.52 |
| ▸ | CA1 known ✓ | P00915 | 1/20 | 0.52 |
| ▸ | THRB known ✓ | P10828 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 5/20 | 0.67 |
| ▸ | LMNA | P02545 | 3/20 | 0.67 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.67 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.67 |
| ▸ | GPR84 | Q9NQS5 | 7/20 | 0.55 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.55 |
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.55 |
| ▸ | SLC22A6 | Q4U2R8 | 2/20 | 0.53 |
| ▸ | PPARD | Q03181 | 6/20 | 0.52 |
| ▸ | PPARA | Q07869 | 6/20 | 0.52 |
| ▸ | HDAC11 | Q96DB2 | 5/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.52 |
| ▸ | TLR2 | O60603 | 2/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.52 |
| ▸ | MEN1 | O00255 | 2/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Octanedioate SCHEMBL9642090 | 1.00 | TSHR (0.67) | TSHRLMNANFKB1PMP22GPR84 | |
| Pimelic Acid SCHEMBL30384892 | 1.00 | TSHR (0.67) | TSHRLMNANFKB1PMP22GPR84 | |
| Sebacic Acid SCHEMBL6135890 | 1.00 | TSHR (0.67) | TSHRLMNANFKB1PMP22GPR84 | |
| Adipic Acid SCHEMBL21489542 | 0.97 | LMNA (0.65) | TSHRLMNANFKB1PMP22GPR84 | |
| Adipic Acid SCHEMBL105756 | 0.97 | LMNA (0.65) | TSHRLMNANFKB1PMP22GPR84 | |
| Potassium Ion SCHEMBL30384886 | 0.94 | TSHR (0.67) | TSHRLMNANFKB1PMP22GPR84 | |
| Azelaic Acid SCHEMBL31148332 | 0.94 | TSHR (0.67) | TSHRLMNANFKB1PMP22GPR84 | |
| Sebacic Acid SCHEMBL29049531 | 0.94 | TSHR (0.67) | TSHRLMNANFKB1PMP22GPR84 | |
| Azelaic Acid SCHEMBL29070842 | 0.94 | TSHR (0.67) | TSHRLMNANFKB1PMP22GPR84 | |
| Azelaic Acid SCHEMBL2380307 | 0.94 | TSHR (0.67) | TSHRLMNANFKB1PMP22GPR84 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3749081-B1 | METHODS AND COMPOSITIONS FOR INCREASING TOLERANCE TO ABIOTIC STRESS IN PLANTS | CROP MICROCLIMATE MAN INC (US) | 2025-05-21 | — | — | EP | disclosed |
| WO-2024177875-A1 | METHODS AND COMPOSITIONS FOR INCREASING TOLERANCE TO ABIOTIC STRESS IN PLANTS | CROP MICROCLIMATE MANAGEMENT INC. (US) | 2024-08-29 | — | — | WO | disclosed |
| US-11638401-B2 | Methods and compositions for increasing tolerance to abiotic stress in plants | CROP MICROCLIMATE MANAGEMENT INC. (US) | 2023-05-02 | — | — | US | disclosed |
| CN-110623949-A | A composition containing azelaic acid monometal salt and Monoxazone for whitening and refining skin, and its preparation method | 天津理工大学 | 2019-12-31 | — | — | CN | disclosed |
| US-20090111875-A1 | Skin care compositions | WHEWELL CHRISTOPHER J | 2009-04-30 | — | — | US | disclosed |
| US-20090110657-A1 | Skin care compositions | WHEWELL CHRISTOPHER J | 2009-04-30 | — | — | US | disclosed |
| US-20080089854-A1 | Skin care compositions | WHEWELL CHRISTOPHER J | 2008-04-17 | — | — | US | disclosed |
| US-20070292382-A1 | SKIN CARE COMPOSITIONS | WHEWELL CHRISTOPHER J | 2007-12-20 | — | — | US | disclosed |
| US-7300957-B1 | Skin care compositions | WHEWELL CHRISTOPHER J | 2007-11-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090110657-A1 | Skin care compositions | CUTA, ELOVL5, SCD5 | PPARG 593/4885PDE4A 2442/4885PDE3A 900/4885 |
| US-20080089854-A1 | Skin care compositions | CUTA, MGLL, LPO | PPARG 401/4885PDE4A 1210/4885PDE3A 360/4885 |
| US-20070292382-A1 | SKIN CARE COMPOSITIONS | CUTA, MGLL, AGPAT5 | PPARG 347/4885PDE4A 1367/4885PDE3A 569/4885 |
| US-20090111875-A1 | Skin care compositions | ELOVL5, CUTA, LPO | PPARG 198/4885PDE4A 1733/4885PDE3A 504/4885 |
| US-11638401-B2 | Methods and compositions for increasing tolerance to abiotic stress in plants | HPD, NOS3, HNMT | PPARG 2565/4885PDE4A 2312/4885PDE3A 2026/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.